R&D Pipeline

PRECLINICAL STATUS: DXL625 (CD20), for the prospective treatment of non-Hodgkin’s lymphoma, a humanized anti-CD20 monoclonal antibody enhanced with InNexus’ Dynamic Cross Linking (DXL™) technology, may afford greater potency, binding affinity, and related characteristics.

DXL™ technology platform (formerly SuperAntibodies™) has a strong intellectual property base that utilizes site-specific chemical conjugation and novel, genetically engineered, fusion proteins to add secondary properties to antibodies (antigen binding is the primary property)

DXL™ expresses improved or novel therapeutic properties. The appeal of the technology platforms to pharmaceutical and biotechnology companies can be manifold, including the ability to:

• Convert existing non-product grade antibodies into ones with product potential. It is suggested that this represents the largest potential use of the technology platforms with thousands of such antibody candidates.
• Increase antibody potency and profitability. Increased potency allows for significant impact on the target and greater overall therapeutic application of the antibody/treatment while possibly decreasing the dosage and cost of goods.
• Extend the patent life of FDA-approved antibody products. There are currently dozens of approved and pending antibody products with combined markets of billions of dollars; such products have consumed one-half to two-thirds of their patent life before reaching the product approval stage.
• Rescue investment in late-stage antibodies that did not meet their clinical endpoints. Typically 10’s of millions can be invested in an antibody to prove efficacy in clinical trials – if it does not have sufficient potency to be approved, DXL™ can be used to create a higher potency version, enter a comparative clinical trial and rapidly complete clinical testing for approval.
• Achieve an “end around” existing patents on antibody diagnostic and therapeutics. Each antibody developed with the DXL™ technology platform likely represents new, patentable inventions; this allows InNexus and it’s partners to pursue products and markets in which there are already established competitors.